Real world outcomes with durvalumab after chemoradiation for stage III NSCLC in an elderly population

Stephen Liu, shared a post on X about a recent paper titled “Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study” published in the Clinical Lung Cancer.

Stephen Liu commented on X sharing the paper:

“Real world outcomes with durvalumab after chemoradiation for stage III NSCLC (PACIFIC) in an elderly population (age ≥75y) at Clinical Lung Cancer. No significant difference in PFS or irAEs between older and younger groups. Overall consistent outcomes with trial.”

Source: Stephen Liu/X                                                                       .

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.